Analysis of the phase 3 randomized clinical trial PERSEPHONE showed that 6 months of treatment with trastuzumab was noninferior to 12 months in terms of disease-free survival, whereas a shorter course of trastuzumab was associated with a 50% reduction in cardiotoxicity.
Chicago, IL—A novel drug is showing significant promise in metastatic breast cancers, offering renewed hope to patients with late-stage, difficult-to-treat solid tumors. According to data presented at ASCO 2018, sacituzumab govitecan demonstrated significant clinical activity as a single agent in heavily pretreated patients with hormone receptor (HR)-positive, HER2-negative metastatic breast [ Read More ]
One of the most important studies presented at ASCO 2018 showed that endocrine therapy alone was noninferior to endocrine therapy plus chemotherapy in women with estrogen receptor (ER)-positive, HER2-negative, node-negative early-stage breast cancer and an intermediate risk score (score, 11-25) on the Oncotype DX gene-expression assay for breast cancer. “Application [ Read More ]
A claims analysis of elderly patients with pancreatic cancer has shown that those receiving early palliative care consultations had lower healthcare utilization than patients who received late palliative care.
San Francisco, CA—Understanding the complex relationship between the PD-1 receptor, its ligand 1 (PD-L1), and mismatch repair deficiency (dMMR) status may help to improve treatment outcomes in patients with resectable gastric and esophageal cancer, according to a retrospective tissue-based analysis.
A new study presented at ASCO 2018 showed that the use of next-generation sequencing of metastatic non–small-cell lung cancer tumors to test for all known cancer-related genetic mutations was more cost-effective and provided faster results than testing for a single genetic mutation.
A new retrospective analysis presented at ASCO 2018 lends support to precision medicine in cancer. In the Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT) clinical trial, selecting a targeted therapy based on patients’ tumor molecular analyses independently predicted longer overall survival (OS) compared with nonmatched therapy across a [ Read More ]
“It’s the disease of not listening that I am troubled with,” a quote attributed to King Henry IV, kicked off a spirited panel discussion on the importance of incorporating the patient’s voice during treatment. Experts addressed these challenges at the 2018 Association of Community Cancer Centers Annual Meeting & Cancer [ Read More ]
“Communication is a beautiful thing, and we stress that a lot in our clinic. The longer a patient is on pain medicine, the harder it is to come off of it and the more it’s going to predict issues later on, so we have to continue to be vigilant,” Ms. Edwards
San Francisco, CA—The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) provides durable clinical benefit in patients with previously treated DNA mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC).